What is LuViva®?
For more information please visit: http://luvivaeurope.com/
Cervical Cancer is the 2nd most common cancer afflicting women worldwide . In many countries, cervical cancer screening programs utilize a Pap test.
If the Pap result is abnormal a visual examination called colposcopy, and in many instances one or more biopsies of the cervix is preformed to detect abnormal cervical tissue. Recently, physicians have started to include a Human papillomavirus (HPV) DNA test in the process in order to determine if a patient has an active infection. Though these tests has proven effective in reducing the number of women dying worldwide from cervical cancer, these tests refer a high percentage of women onto unnecessary tests and procedures and in some case misses the pre-cancerous tissue entirely12,3,4,51.
The LuViva ® Advanced Cervical Scan is designed for use on women who have been referred for additional testing or for a colposcopic examination after receiving an abnormal Pap test, a positive HPV test and/or are exhibiting other cervical cancer high-risk factors (see Chart 1).
The device works by simply shining light onto the cervix and measuring the light that is reflected back using fluorescence and reflectance spectrometry.
Taking less than one minute to administer, the test is painless and the physician receives results immediately.
How LuViva® Helps
Since LuViva is used on the patient prior to additional testing or the colposcopy/biopsy exam, its ability to detect the presence of precancerous cells on the cervix can benefit the patient, physician and payer in either two ways.
- If LuViva indicates the likelihood of precancerous cells is low, then based on the patient’s medical history and other risk factors, the physician will determine if the patient can be sent home and no colposcopic exam is needed. The patient is happy to know immediately that she did not have to have an unnecessary biopsy and there is no disease present. The physician is able to focus his/her attention on patients that have actual disease. The payer did not have to pay for an unnecessary and costly procedure.
- If LuViva indicates the likelihood of precancerous cells is medium to high, based on the patient’s medical history and other risk factors, the physician will determine if the patient will go onto colposcopy. The patient will have the satisfaction of knowing immediately that she is receiving the highest standard of care. The physician will have more confidence that actual disease is present and his/her decision to biopsy or perform some other treatment to the cervix will be supported by objective, spectroscopic data. The payer will have additional documentation that a costly procedure was necessary.